Ampio adds new hospitals in trial for inhalation treatment of COVID-19

Ampio adds new hospitals in trial for inhalation treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation... Read More

Wednesday February 24, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso, COVID-19

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus... Read More

Tuesday February 2, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More

Tuesday January 5, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, COVID-19

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it received guidance from the U.S Food Drug Administration regarding the impact of COVID-19 on its Phase III clinical... Read More

Wednesday December 30, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA

Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hascompleted its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for... Read More

Friday December 18, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug,... Read More

Monday December 14, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, FDA, COVID-19

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More

Wednesday November 11, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, Michael Macaluso, COVID-19